moxifloxacin has been researched along with pantoprazole in 10 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (pantoprazole) | Trials (pantoprazole) | Recent Studies (post-2010) (pantoprazole) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 1,467 | 476 | 579 |
| Protein | Taxonomy | moxifloxacin (IC50) | pantoprazole (IC50) |
|---|---|---|---|
| Solute carrier family 22 member 2 | Homo sapiens (human) | 1.5 | |
| Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | 2.8 | |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 7.75 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (50.00) | 29.6817 |
| 2010's | 5 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Conners, GP; Hays, DP | 1 |
| Altintaş, E; Sezgin, O; Tellioğlu, B; Tombak, A; Uçbilek, E | 1 |
| Cellini, L; Ciccaglione, AF; Grossi, L; Marzio, L | 1 |
| Bago, J; Dominković, L; Gulić, S; Majstorović Barać, K; Marušić, M; Pezerović, D | 1 |
1 review(s) available for moxifloxacin and pantoprazole
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for moxifloxacin and pantoprazole
| Article | Year |
|---|---|
Low efficacy rate of moxifloxacin-containing Helicobacter pylori eradication treatment: in an observational study in a Turkish population.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Aza Compounds; Drug Therapy, Combination; Dyspepsia; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Moxifloxacin; Pantoprazole; Peptic Ulcer; Pilot Projects; Quinolines; Treatment Outcome; Turkey | 2007 |
Quadruple therapy with moxifloxacin and bismuth for first-line treatment of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Infective Agents; Aza Compounds; Drug Therapy, Combination; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Moxifloxacin; Organometallic Compounds; Pantoprazole; Proton Pump Inhibitors; Quinolines; Treatment Outcome | 2012 |
7 other study(ies) available for moxifloxacin and pantoprazole
| Article | Year |
|---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Emergency department drug orders: does drug storage location make a difference?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Infective Agents; Anti-Ulcer Agents; Aza Compounds; Azithromycin; Drug Storage; Drug Utilization; Emergency Service, Hospital; Fluoroquinolones; Hospitals, Urban; Humans; Injections; Medical Order Entry Systems; Medication Systems, Hospital; Moxifloxacin; Pantoprazole; Pharmacies; Quinolines; Retrospective Studies | 2007 |
Bismuth-based quadruple therapy modified with moxifloxacin for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Breath Tests; Drug Therapy, Combination; Female; Fluoroquinolones; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Moxifloxacin; Organometallic Compounds; Pantoprazole; Patient Compliance; Proton Pump Inhibitors; Retrospective Studies; Treatment Outcome | 2017 |